Trodelvy plus Keytruda effective for aggressive breast cancer type: Gilead Sciences Ruchika Sharma23 April 2025 5:00 AMFoster City: Gilead Sciences, Inc. has announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that...
Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy Ruchika Sharma19 Dec 2024 8:00 AMFoster City: Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy...
Gilead Sciences Trodelvy, Keytruda combo study demonstrates promising clinical activity in first-line Metastatic Non-Small Cell Lung Cancer Ruchika Sharma12 Sept 2023 9:00 AMFoster City: Gilead Sciences, Inc. has announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy...
Gilead Sciences Trodelvy under USFDA priority review for adult patients with pretreated metastatic breast cancer Ruchika Sharma14 Oct 2022 9:00 AMTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Gilead Sciences cancer drug Trodelvy gets speedy USFDA approval Ruchika Sharma14 April 2021 10:41 AMFoster City: Drugmaker, Gilead Sciences, has recently announced that the U.S. Food and Drug Administration (USFDA) has granted accelerated...
Gilead Sciences application for breast cancer therapy gets EMA validation Ruchika Sharma28 March 2021 5:30 AMFoster City: Gilead Sciences has recently announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application...
